Citigroup Inc. began coverage on shares of Seres Therapeutics, Inc. (NASDAQ:MCRB) in a research note issued on Thursday, The Fly reports. The firm set a “positive” rating and a $19.00 price target on the biotechnology company’s stock. Citigroup Inc.’s target price points to a potential upside of 74.79% from the stock’s current price.

Several other research analysts have also weighed in on the stock. Zacks Investment Research lowered shares of Seres Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday. Seaport Global Securities reissued a “buy” rating and set a $20.00 target price on shares of Seres Therapeutics in a research report on Friday, October 6th. Cowen and Company reissued a “buy” rating on shares of Seres Therapeutics in a research report on Monday, October 2nd. ValuEngine downgraded shares of Seres Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, September 21st. Finally, Cantor Fitzgerald reissued a “buy” rating on shares of Seres Therapeutics in a research report on Wednesday, August 30th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $17.71.

Shares of Seres Therapeutics (MCRB) traded down 0.91% during midday trading on Thursday, hitting $10.87. 166,243 shares of the company’s stock were exchanged. The firm’s market cap is $440.37 million. The stock’s 50-day moving average price is $14.35 and its 200 day moving average price is $14.35. Seres Therapeutics has a one year low of $8.85 and a one year high of $17.42.

Seres Therapeutics (NASDAQ:MCRB) last announced its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.69) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.59) by ($0.10). The company had revenue of $3.00 million for the quarter, compared to analysts’ expectations of $3.00 million. Seres Therapeutics had a negative return on equity of 80.21% and a negative net margin of 441.38%. The company’s revenue was up .0% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.70) earnings per share. Equities research analysts forecast that Seres Therapeutics will post ($2.55) EPS for the current year.

WARNING: This article was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another site, it was illegally copied and reposted in violation of US and international copyright legislation. The correct version of this article can be read at https://www.americanbankingnews.com/2017/10/12/seres-therapeutics-inc-mcrb-earns-positive-rating-from-analysts-at-citigroup-inc.html.

A number of large investors have recently modified their holdings of MCRB. Jennison Associates grew its position in Seres Therapeutics by 0.4% in the third quarter. Jennison Associates now owns 391,700 shares of the biotechnology company’s stock valued at $11,610,000 after acquiring an additional 1,700 shares in the last quarter. ProShare Advisors LLC acquired a new stake in Seres Therapeutics in the fourth quarter valued at approximately $1,146,000. Morgan Stanley grew its position in Seres Therapeutics by 225.3% in the fourth quarter. Morgan Stanley now owns 33,758 shares of the biotechnology company’s stock valued at $1,185,000 after acquiring an additional 23,381 shares in the last quarter. Jennison Associates LLC grew its position in Seres Therapeutics by 1.9% in the fourth quarter. Jennison Associates LLC now owns 398,959 shares of the biotechnology company’s stock valued at $13,999,000 after acquiring an additional 7,259 shares in the last quarter. Finally, BlackRock Advisors LLC grew its position in Seres Therapeutics by 0.7% in the fourth quarter. BlackRock Advisors LLC now owns 340,871 shares of the biotechnology company’s stock valued at $11,962,000 after acquiring an additional 2,443 shares in the last quarter. 74.76% of the stock is owned by institutional investors.

About Seres Therapeutics

Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.

The Fly

Analyst Recommendations for Seres Therapeutics (NASDAQ:MCRB)

Receive News & Ratings for Seres Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.